The cell and gene therapy manufacturing services market size is projected to reach US$ 26,724.90 million by 2030 from US$ 7,581.97 million in 2022. The market is expected to register a CAGR of 17.1% during 2022–2030. Automation of manufacturing services for cell and gene therapy is likely to remain a key trend in the market.
In recent years, the outsourced cell and gene manufacturing sector has undergone significant expansion and change. As cell and gene therapies progress, drug innovator firms are progressively depending on service providers to fulfill their manufacturing requirements. Outsourcing enables innovators to take advantage of the specialized expertise and capabilities of contract development and manufacturing organizations (CDMOs) to reduce costs and expedite time to market. The landscape of cell and gene therapy manufacturing has evolved over the past five years, with a shift towards more sophisticated platforms allowing scale-up, increased automation, and enhanced quality systems, shaping the contract manufacturing industry. With the growing number of approved cell and gene therapy products in the market each year, the need to enhance processes is becoming increasingly important.
Both publicly and privately funded contract biopharmaceutical manufacturing has increased as a result of the surge in new biopharmaceutical products competing for approval. As a result, while established industry players are attempting to hold onto their positions and lead, new organizations are engaged in providing manufacturing services for cell and gene therapy. Healthcare policies in many regions now prioritize the ability to manufacture pharmaceutical (small molecule) products of all kinds. Additionally, a shift toward larger-molecule biomanufacturing, recombinant therapies, and increasingly complex biologics has occurred in many regions.
Significant therapeutic advances in cell and gene therapy manufacturing services have resulted from the growing cell therapy research activities. The industry is striving to expand its manufacturing scale and overall accessibility to a broader population while emphasizing the advantages of advanced therapy medicinal products (ATMPs). The increasing complexity of personalized medicine necessitates the development of manufacturing capabilities to keep up with demand and guarantee patient access to these innovative treatments. Contract manufacturing now has more options due to the rise in global production. Funding for newly approved biopharmaceutical products, as well as contract biopharmaceutical manufacturing, has increased from both public and private sources. Worldwide organizations offer manufacturing services for cell and gene therapy, and well-established industry participants strive to sustain their operations. Thus, the emerging focus on the development of cell therapy manufacturing is likely to drive the growth of the market.
Because of the rise in approvals and investments, there is an increasing need to manufacture therapies at preclinical, clinical, and commercial stages. Key players are making strategic development investments, which are opening up a lot of market opportunities. As an illustration of the rising need for cell and gene therapy manufacturing services, Bristol Myers Squibb and the start-up Cellares inked a $380 million deal in May 2024. In August 2023, Cellares completed a $255 million series C funding round, with BMS among the investors. Cellares will make chimeric antigen receptor (CAR) T-cell treatments for BMS. BMS will reserve spaces in Cellares' automated cell therapy manufacturing machines, or Cell Shuttle machines, in accordance with the terms of the agreement. With the money from the BMS sale, Cellares intends to open more locations in the US, Europe, and Japan in addition to running the ones in San Francisco and New Jersey.
Key segments that contributed to the derivation of the cell and gene therapy manufacturing services market analysis are type, indication, application, and end user.
The geographic scope of the cell and gene therapy manufacturing services market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The market for manufacturing services related to cell and gene therapy is anticipated to expand as a result of the rising demand for these products. This growth is linked to an increase in startups, an increase in R&D activities, and increased investments in the construction of cell and gene therapy manufacturing facilities in the US and Canada.
Additionally, for the forecast period, the Asia Pacific market has grown significantly at a robust CAGR. This growth can be attributed to a number of factors, including the growing need for advanced treatment solutions, favorable regulatory scenarios, and an increasing emphasis on research and development activities. Additionally, during the forecast period, the Asia Pacific market is expected to be driven by the expansion of healthcare infrastructure and rising investments meant to stimulate research activities.
The regional trends and factors influencing the Cell and Gene Therapy Manufacturing Services Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cell and Gene Therapy Manufacturing Services Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 7,581.97 Million |
| Market Size by 2030 | US$ 26,724.90 Million |
| Global CAGR (2022 - 2030) | 17.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Cell and Gene Therapy Manufacturing Services Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Cell and Gene Therapy Manufacturing Services Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The cell and gene therapy manufacturing services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the cell and gene therapy manufacturing services market are listed below:
The “Cell and Gene Therapy Manufacturing Services Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
North America dominated the cell and gene therapy manufacturing services market in 2022
Key factors driving the market are increase in demand for cell and gene therapy manufacturing and the emergence of new startup service providers.
Automation of manufacturing services for cell and gene therapy is likely to remain a key trend in the market.
Thermo Fisher Scientific Inc, Merck KGaA, Charles River Laboratories International Inc, Lonza Group AG, WuXi AppTec Co Ltd, Catalent Inc, Takara Bio Inc, Nikon Corp, FUJIFILM Holdings Corp, National Resilience Inc, Oxford BioMedica Plc.
The market is expected to register a CAGR of 17.1% during 2022–2030.